China Pharma Holdings, Inc. (CPHI)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-15

Key Insights

  • Revenue declined 13.4% YoY to $983,536 in Q1 2026, while gross margin improved dramatically to 29% from negative 12%, indicating better cost management but continued revenue challenges in the core business.
  • Intangible assets nearly doubled from $24.1M to $38.7M due to a significant stock issuance (25M shares for $15M), diluting existing shareholders while potentially signaling acquisition or major business expansion.
  • Operating expenses surged 125% YoY driven primarily by G&A costs ($1.2M vs $507K), resulting in a net loss of $1.14M despite gross profit improvement, suggesting operational inefficiency or one-time charges.
  • Cash position deteriorated 51% to $168K from $345K while carrying $1.47B in related-party debt and $1.93M in credit lines, raising serious liquidity concerns for a smaller reporting company with negative cash flows.
Current Report Filed: 2026-03-03

Key Insights

  • China Pharma Holdings, Inc. has entered into a technology transfer agreement to acquire the ownership of an invention patent for Prinsepia Utilis Esterol Sublingual Tablets and its preparation method.
  • The company will issue 12.6 million restricted shares of common stock, valued at $0.55 per share, to pay the $6.93 million transfer price.
  • The technology transfer agreement includes the Transferor providing relevant technical services such as product R&D, registration materials, and other support.

Filings on this page are at least 90 days old. In the app, any new China Pharma Holdings, Inc. filing is analysed the moment you open it.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.